Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC (2022 Version)

Chinese Society Of Clinical Oncology (Csco) Non-Small Cell Lung Cancer Committee ,Anti-Cancer Drug Safety Management Committee (Asmc)

doi:10.3779/j.issn.1009-3419.2022.101.47

Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC (2022 Version)

Chinese Society Of Clinical Oncology (Csco) Non-Small Cell Lung Cancer Committee , Anti-Cancer Drug Safety Management Committee (Asmc)

https://doi.org/10.3779/j.issn.1009-3419.2022.101.47

Copy DOI

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer	Publication Date: Sep 20, 2022
Citations: 3	License type: CC BY 3.0

#EGFR Mutated NSCLC #Third-generation EGFR-TKI + Show 1 more

Abstract
Full-Text
Similar Papers

Abstract

【中文题目：三代EGFR-TKI在EGFR突变NSCLC治疗中应用的专家共识（2022年版）】【中文关键词：肺肿瘤；受体蛋白酪氨酸激酶；ErbB受体；共识】.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Zhongguo fei ai za zhi = Chinese journal of lung cancer

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.